Bluebird bio Inc (BLUE)

NASDAQ
6.72
+0.41(+6.50%)
After Hours
6.95
+0.23(+3.42%)
- Real-time Data
  • Volume:
    7,271,740
  • Day's Range:
    6.33 - 7.00
  • 52 wk Range:
    2.87 - 25.39

BLUE Overview

Prev. Close
6.31
Day's Range
6.33-7
Revenue
35.76M
Open
6.39
52 wk Range
2.87-25.39
EPS
-8.23
Volume
7,271,740
Market Cap
518.26M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
8,175,206
P/E Ratio
-0.782
Beta
1.33
1-Year Change
-64.31%
Shares Outstanding
77,121,751
Next Earnings Date
02 Nov 2022
What is your sentiment on Bluebird?
or
Market is currently closed. Voting is open during market hours.

Bluebird bio Inc Analysis

Bluebird bio Inc Company Profile

Bluebird bio Inc Company Profile

Employees
518

bluebird bio, Inc. is a biotechnology company. The Company is principally focused on researching, developing and commercializing gene therapies for genetic diseases. The Company’s gene therapy programs in genetic diseases include programs for B-thalassemia; LentiGlobin product candidate as a treatment for sickle cell disease (SCD), and elivaldogene autotemcel (eli-cel) as a treatment for cerebral adrenoleukodystrophy (CALD). It is using a lentiviral vector (LVV) platform, it custom designs each of its therapies to address the underlying cause of disease. The Company is developing lovotibeglogene autotemcel (lovo-cel) as a one-time treatment for patients with SCD, a genetic disease caused by a single mutation in the B-globin gene that leads to the production of abnormal sickle hemoglobin (HbS). The BLA for betibeglogene autotemcel (beti-cel) is for B-thalassemia in patients who receive regular red blood cell (RBC) transfusions.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyBuyStrong BuySell
Technical IndicatorsBuySellStrong BuyStrong BuyStrong Sell
SummaryBuyNeutralStrong BuyStrong BuyStrong Sell
  • На чем летим?
    0